Evidence map›Paper›PMID 37149081›Full record

ArticleProgress in neurobiology2023

Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.

Anoushka Lotun, Danning Li, Hongxia Xu, Qin Su, Serafettin Tuncer, Julio Sanmiguel, Morgan Mooney, Christina E Baer, Russell Ulbrich, Stephen J Eyles and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Progress in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The Emerging Role of N-Acetylaspartate in Cancer.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Enhancing Spatial Transcriptomics via Spatially Constrained Matrix Decomposition with EDGES.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  5. Current clinical applications of AAV-mediated gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  7. Review
  8. Review
  9. UrineHuman gene therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Anoushka LotunHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Danning LiHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Hongxia XuHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA; University of Science and Technology of Kunming, People's Republic of China.
Qin SuHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Serafettin TuncerHeinrich Heine University, Medical School, Duesseldorf, Germany.
Julio SanmiguelHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Morgan MooneyHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Christina E BaerSanderson Center for Optical Experimentation, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Russell UlbrichScientiaLux LLC, Tissue-Gnostics USA-East, Worcester, MA, USA.
Stephen J EylesMass Spectrometry Core, University of Massachusetts, Amherst, MA, USA.
Lara StrittmatterElectron Microscopy Core, University of Massachusetts Chan Medical School, MA, USA.
Lawrence J HaywardDepartment of Neurology, University of Massachusetts Chan Medical School, MA, USA.
Dominic J GesslerHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA; Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA. Electronic address: dominic.gessler@umassmed.edu.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA, USA; Department of Microbiology & Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: guangping.gao@umassmed.edu.
University of Massachusetts Chan Medical School · USHeinrich Heine University Düsseldorf · DEUniversity of Massachusetts Amherst · USUniversity of Minnesota · US

Funding

Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Dan Wang · 2021 to 2026
$19.5M
Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0M
Viral escape from AAV expressed transgenesP01AI100263 · NIAID · SCRIPPS FLORIDA · PI GAO, GUANGPING · 2012 to 2016
$11.9M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XUE, WEN · 2016 to 2020
$11.3M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
Safety and efficacy of optimized AAV3 vectors in murine and NHP liversR21EB015684 · NIBIB · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, SRIVASTAVA, ARUN · 2012 to 2013
$432k
A novel bone-targeting AAV-mediated gene therapy to promote bone formation in osteoporosisR21AR077557 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SHIM, JAE-HYUCK · 2021 to 2022
$403k
NHLBI NIH HHS P01 HL131471NHLBI NIH HHS P01 HL158506NHLBI NIH HHS R01 HL097088NHLBI NIH HHS R01 HL152723NHLBI NIH HHS UG3 HL147367NHLBI NIH HHS UH3 HL147367NIAID NIH HHS P01 AI100263NIAID NIH HHS R01 AI121135NIAID NIH HHS U19 AI149646NIAMS NIH HHS R21 AR077557NIBIB NIH HHS R21 EB015684NINDS NIH HHS R01 NS076991
6 · The paper itself

Abstract

Myelinating oligodendrocytes are essential for neuronal communication and homeostasis of the central nervous system (CNS). One of the most abundant molecules in the mammalian CNS is N-acetylaspartate (NAA), which is catabolized into L-aspartate and acetate by the enzyme aspartoacylase (ASPA) in oligodendrocytes. The resulting acetate moiety is thought to contribute to myelin lipid synthesis. In addition, affected NAA metabolism has been implicated in several neurological disorders, including leukodystrophies and demyelinating diseases such as multiple sclerosis. Genetic disruption of ASPA function causes Canavan disease, which is hallmarked by increased NAA levels, myelin and neuronal loss, large vacuole formation in the CNS, and early death in childhood. Although NAA's direct role in the CNS is inconclusive, in peripheral adipose tissue, NAA-derived acetate has been found to modify histones, a mechanism known to be involved in epigenetic regulation of cell differentiation. We hypothesize that a lack of cellular differentiation in the brain contributes to the disruption of myelination and neurodegeneration in diseases with altered NAA metabolism, such as Canavan disease. Our study demonstrates that loss of functional Aspa in mice disrupts myelination and shifts the transcriptional expression of neuronal and oligodendrocyte markers towards less differentiated stages in a spatiotemporal manner. Upon re-expression of ASPA, these oligodendrocyte and neuronal lineage markers are either improved or normalized, suggesting that NAA breakdown by Aspa plays an essential role in the maturation of neurons and oligodendrocytes. Also, this effect of ASPA re-expression is blunted in old mice, potentially due to limited ability of neuronal, rather than oligodendrocyte, recovery.

Indexed as

Canavan DiseaseAnimalsAspartic AcidCell LineageCentral Nervous SystemEpigenesis, GeneticMammalsMiceMyelin SheathOligodendrogliaAspartic AcidN-acetylaspartateAAVCanavan diseaseCNSDemyelinationGene therapyN-acetylaspartateNeurodegenerationNeuronsOligodendrocytes

Identifiers

PMID37149081
PMCPMC10330635
OpenAlexW4368341681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.